Eli Lilly (LLY)

1,148.84
-6.13 (-0.53%)
NYSE· Last Trade: Jul 31st, 5:31 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,154.97
Open1,148.51
Bid1,145.25
Ask1,148.84
Day's Range1,119.00 - 1,150.63
52 Week Range623.78 - 1,249.45
Volume2,880,275
Market Cap1.10T
PE Ratio (TTM)50.06
EPS (TTM)22.9
Dividend & Yield6.920 (0.60%)
1 Month Average Volume2,450,168

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.fool.com
The global market for obesity drugs is soaring, yet Lilly has a dominant market share.
Via The Motley Fool · July 31, 2026
XLV vs. IHE: Which Healthcare ETF Is the Better Buy?fool.com
IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio.
Via The Motley Fool · July 31, 2026
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?fool.com
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
Via The Motley Fool · July 31, 2026
Eli Lilly (NYSE:LLY): A Quality Dividend Stock with Sustainable Growth and Strong Fundamentalschartmill.com
Via Chartmill · July 28, 2026
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levelsinvestors.com
Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced pressure.
Via Investor's Business Daily · July 31, 2026
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Targetfool.com
There are other reasons to pay attention to Viking Therapeutics.
Via The Motley Fool · July 30, 2026
VHT vs. PBE: Which Health Care ETF Is the Better Buy?fool.com
PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost option.
Via The Motley Fool · July 30, 2026
Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stockbenzinga.com
CNBC's Mad Money Lightning Round: Cramer says Astera Labs (ALAB) is a buy, but doesn't care for Rigetti Computing (RGTI). Eli Lilly (LLY) is a classic own, don't trade. MakeMyTrip (MMYT) coverage initiated with Buy rating.
Via Benzinga · July 30, 2026
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Nowfool.com
But is that performance sustainable?
Via The Motley Fool · July 29, 2026
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Holdfool.com
They may profit from the rapidly growing GLP-1 market in very different ways.
Via The Motley Fool · July 29, 2026
State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?fool.com
FBT delivered 48.5% returns over one year but carries a 0.55% expense ratio and experiences greater volatility. XLV offers lower costs, with an 0.08% expense ratio, as well as broader diversification across 60 healthcare stocks.
Via The Motley Fool · July 29, 2026
Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stockfool.com
Lilly's pipeline is on track to pick up a handful of interesting new programs.
Via The Motley Fool · July 29, 2026
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patientsfool.com
Will this pharma company become a new leader in the weight loss market?
Via The Motley Fool · July 29, 2026
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growthfool.com
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.
Via The Motley Fool · July 29, 2026
Only 2 "Magnificent Seven" Stocks Are Beating the Market This Year. What's Going On?fool.com
The market has hit new records this year, but it isn't the "Magnificent Seven" stocks that are leading the way.
Via The Motley Fool · July 29, 2026
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.fool.com
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.
Via The Motley Fool · July 29, 2026
4 Stocks That Can 4x Your Money in 4 Yearsfool.com
Quadrupling your money in four years is an incredible rate of return.
Via The Motley Fool · July 28, 2026
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugsfool.com
The company isn't resting on its laurels.
Via The Motley Fool · July 28, 2026
VUG vs. VTI: Which Vanguard ETF Is the Better Buy for Growth Stocks?fool.com
Can growth stocks maintain their momentum, or is it time to diversify?
Via The Motley Fool · July 28, 2026
Where Will Novo Nordisk Stock Be in 3 Years?fool.com
Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.
Via The Motley Fool · July 28, 2026
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Feesfool.com
VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.
Via The Motley Fool · July 28, 2026
SCHD vs. VIG: Which Dividend ETF Could Build More Wealth Over 20 Years?fool.com
The Schwab U.S. Dividend Equity ETF has the superior selection strategy, while the Vanguard Dividend Appreciation ETF has a bigger growth and tech tilt.
Via The Motley Fool · July 28, 2026
XLV vs IYH: Which Healthcare ETF Wins on Cost and Yield?fool.com
State Street's fund charges just 0.08% annually versus 0.38% for iShares, but the broader portfolio offers 100 holdings versus 60.
Via The Motley Fool · July 27, 2026
XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio?fool.com
State Street's concentrated 60-stock approach outpaced Fidelity's broader 365-holding fund over five years, though both charge identical 0.08% fees.
Via The Motley Fool · July 27, 2026
3 Quality Compounders to Own for Decades
A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits...
Via StockStory · July 27, 2026